Article de revue

Public health impact and cost-effectiveness of the RTS,S/AS01 malaria vaccine: a systematic comparison of predictions from four mathematical models

Melissa A. Penny, Robert Verity, Caitlin A. Bever, Christophe Sauboin, Katya Galactionova, Stefan Flasche, Michael T. White, Edward A. Wenger, Nicolas Van de Velde, Peter Pemberton-Ross, Jamie T. Griffin, Thomas A. Smith, Philip A. Eckhoff, Farzana Muhib, Mark Jit, Azra C. Ghani

The phase 3 trial of the RTS,S/AS01 malaria vaccine candidate showed modest efficacy of the vaccine against Plasmodium falciparum malaria, but was not powered to assess mortality endpoints. Impact projections and cost-effectiveness estimates for longer timeframes than the trial follow-up and across a range of settings are needed to inform policy recommendations. We aimed to assess the public health impact and cost-effectiveness of routine use of the RTS,S/AS01 vaccine in African settings.

 

Auteurs

Langues

  • Anglais

Année de publication

2016

Journal

The Lancet

Volume

10016

Type

Article de revue

Catégories

  • Vaccins et dispositifs d'administration

Maladies

  • Paludisme

Mots-clés

  • Introduction de nouveaux vaccins

Ajouté par: Moderator

Ajouté le: 2016-01-25 05:47:49

Consultations: 1612

Liens

Ajouter une ressource